ReviewJournal of contemporary brachytherapy2026
Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer.
Review in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: High-dose-rate brachytherapy (HDR-BT) is an established and highly effective modality for the radical treatment of localized prostate cancer. Despite its widespread use in Poland, relevant aspects of patient selection, treatment qualification, dose and fractionation, integration with external beam radiotherapy (EBRT), and target and organ-at-risk definition vary between centers. The aim of this document was to develop national recommendations and expert consensus statements to standardize the use of radical HDR-BT for prostate cancer. Material and methods: The Polish Brachytherapy Society convened a multidisciplinary panel of radiation oncologists with extensive experience in prostate brachytherapy. Recommendations were developed through a structured literature review focusing on prospective trials, meta-analyses, and large retrospective studies. Evidence quality and strength of recommendations were assessed using the GRADE framework. A modified two-round Delphi process was applied, involving a core expert panel and an extended national panel. Consensus was predefined as ≥ 75% agreement. Results: Consensus recommendations were formulated across the entire HDR-BT treatment pathway, including patient assessment, diagnostic work-up, risk stratification, indications for HDR-BT monotherapy and HDR-BT boost combined with EBRT, dose and fractionation schedules, use and duration of androgen deprivation therapy, timing of HDR-BT relative to EBRT, and target volume delineation with organ-at-risk dose constraints. The consensus supports fractionated HDR-BT monotherapy in selected low- and intermediate-risk clinical scenarios, and confirms the role of HDR-BT boost combined with EBRT as a key component of dose-escalation strategies in high- and very high-risk prostate cancer. An EQD Conclusions: These recommendations represent the first national expert consensus of the Polish Brachytherapy Society on radical HDR-BT for prostate cancer. They provide a comprehensive, evidence-informed framework to harmonize clinical practice, support decision-making, and improve comparability of outcomes across Polish centers. Regular updates will be required as new clinical evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.